Targeting the PI3K signaling pathway in KRAS mutant colon cancer

Cancer Medicine

Volumn 5, Issue 2, 2016, Pages 248-255

  Hong, Suntaek ^a   Kim, Soyoung ^a   Kim, Hye Youn ^a   Kang, Myunghee ^a   Jang, Ho Hee ^a   Lee, Won Suk ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

KRAS; BKM120; Colon cancer; Combination therapy; PIK3CA

Indexed keywords

BUPARLISIB; CETUXIMAB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; CASPASE 3; MORPHOLINE DERIVATIVE; NVP-BKM120; PROTEIN KINASE B; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DLD 1 CELL LINE; DRUG TARGETING; ENZYME PHOSPHORYLATION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KRAS GENE; LOVO CELL LINE; MALE; MOUSE; NONHUMAN; ONCOGENE; PI3KCA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; COLONIC NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CETUXIMAB; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; MORPHOLINES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85006198800     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.591     Document Type: Article

References (20)

1. Venook, A. P., D. Niedzwiecki, H.-J. Lenz, F. Innocenti, M. R. Mahoney, B. H. O'Neil, et al. 2014. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). ASCO Meet Abstr. 32(15_suppl.):LBA3.
2. Iii, H. A. B. 2013. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother. Pharmacol. 71:829-842.
3. Liao, X., T. Morikawa, P. Lochhead, Y. Imamura, A. Kuchiba, M. Yamauchi, et al. 2012. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18:2257-2268.
4. Van Cutsem, E., C.-H. Köhne, E. Hitre, J. Zaluski, C.-R. Chang Chien, A. Makhson, et al. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360:1408-1417.
5. Bokemeyer, C., I. Bondarenko, A. Makhson, J. T. Hartmann, J. Aparicio, F. de Braud, et al. 2009. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27:663-671.
6. Mueller A, E. Bachmann, M. Linnig, K. Khillimberger, C. C. Schimanski, P. R. Galle, et al. 2012. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol. 69:1601-1615.
7. Laurent-Puig, P., A. Cayre, G. Manceau, E. Buc, J.-B. Bachet, T. Lecomte, et al. 2009. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27:5924-5930.
8. Kurtz, J.-E., and I. Ray-Coquard 2012. PI3 kinase inhibitors in the clinic: an update. Anticancer Res. 32:2463-2470.
9. Koul, D., J. Fu, R. Shen, T. A. LaFortune, S. Wang, N. Tiao, et al. 2012. Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 18:184-195.
10. Zheng, Y., J. Yang, J. Qian, L. Zhang, Y. Lu, H. Li, et al. 2011. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J. Mol. Med. 90:695-706.
11. Maira, S.-M., S. Pecchi, A. Huang, M. Burger, M. Knapp, D. Sterker, et al. 2012. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 11:317-328.
12. Tredan, O., D. Pissaloux, I. Treilleux, Q. Wanq, N. Bonichon-Lamichhane, V. Mari, et al. 2011. PP 86 Immunohistochemistry and molecular biology of the PI3K pathway did not correlate with treatment efficacy of everolimus as second line or third line treatment of advanced endometrial carcinoma. Eur. J. Cancer 1:S32.
13. Cavazzoni, A., R. R. Alfieri, D. Cretella, F. Saccani, L. Ampollini, M. Galetti, et al. 2012. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Mol. Cancer. 11:91.
14. Park, E., J. Park, S.-W. Han, S.-A. Im, T.-Y. Kim, D.-Y. Oh, et al. 2012. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int. J. Oncol. 40:1259-1266.
15. Brachmann, S. M., I. Hofmann, C. Schnell, C. Fritsch, S. Wee, H. Lane, et al. 2009. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 106:22299-22304.
16. Roy, S. K., R. K. Srivastava, and S. Shankar 2010. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J. Mol. Signal. 5:10.
17. Bendell, J. C., J. Rodon, H. A. Burris, M. de Jonge, J. Verweij, D. Birle, et al. 2012. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30:282-290.
18. Pal, I., and M. Mandal 2012. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol. Sin. 33:1441-1458.
19. Engelman, J. A. 2009. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9:550-562.
20. Janku, F., J. J. Wheler, S. N. Westin, S. L. Moulder, A. Naing, A. M. Tsimberidou, et al. 2012. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 30:777-782.